Olon SpA, the Italy-based active pharmaceutical ingredients (API) contract development and manufacturing organisation (CDMO) and generics supplier, has acquired Ricerca Biosciences’ chemical division of the contract research (CRO) and CDMO based in Concord, Ohio (USA). This acquisition strengthens the service offering of Olon for the pharmaceutical and biotech industry, and to benefits the Ricerca Biosciences customer base by providing large scale manufacturing capabilities in Europe.
“By acquiring a research and manufacturing base in the US, Olon will have the opportunity to accelerate growth by adding new CDMO projects and to develop new Generic products for the American market,” commented Paolo Tubertini, CEO of Olon.
Luca Mantovani, Olon managing board member, added, "We are delighted to add Ricerca Biosciences to Olon Group, as this strategic step will broaden our contract research and manufacturing services for all our global customers.”
Ricerca Biosciences is the US-based CRO supporting the development and manufacture of APIs and performance materials in support clinical supply, market development and commercial distribution.